NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-AG-20-019 from the NIH Guide for Grants and Contracts. This FOA supports applications for Claude D. Pepper Older Americans Independence Centers (OAICs), centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. The OAIC awards are designed to develop or strengthen awardee institutions programs that focus and sustain progress on a key area in aging research related to the mission of the OAIC program.
Funding Opportunity RFA-HL-20-007 from the NIH Guide for Grants and Contracts. To establish a set of complementary model systems that reproduce essential disease-defining features of human idiopathic pulmonary fibrosis (IPF). This collection of models will advance our understanding of the pathogenesis of IPF from its onset through disease progression and serve as a resource for the broader research community, including investigators developing and testing novel therapies to treat this fatal disease.
Notice NOT-HL-19-705 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-20-140 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. This includes technologies that do not rely on the use of human fetal tissue, as described in NOT-19-042. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.
Funding Opportunity RFA-DA-20-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for a single Coordinating Center to support novel data acquisition strategies, data harmonization, analysis and dissemination activities on emerging and current drug abuse trends across the United States. The Coordinating Center will (1) Maintain a Scientific Advisory Group; (2) Maintain and refine an Early Warning Network composed of local experts on drug abuse data from the selected communities, as well as NIDA-supported community-based researchers, to assist in the ongoing monitoring and interpretation of data; (3) Maintain key community-level indicators for monitoring drug abuse trends and early identification of new synthetic drugs and emerging issues including establishing harmonization of indicators and of presentation and analysis of indicators across the selected communities; (4) Continue to identify and maintain novel sources of data including treatment admissions data, national drug use among adults and youth, law enforcement seizures, and drug poisoning death; (5) Conduct cross-site data analyses from the harmonized Coordinating Center data; (6) Continue to disseminate and identify novel ways to execute dissemination and publication plans of results and findings from the Coordinating Center data, including development and maintenance of a website for disseminating data and findings; (7) Conduct webinars on topics of interest to stakeholders; (8) Conduct on the ground epidemiologic investigations on topics of immediate crisis or need, providing functional feedback to impacted communities towards optimizing current and future response; (9) Provide operational, administrative and logistical support for the Coordinating Center data harmonization and dissemination initiative.
Notice NOT-HL-19-707 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-706 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-19-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions to participate in the Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP), for the development of preclinical porcine-to-nonhuman primate (NHP) models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The goals of this program are to: (1) delineate the cellular and molecular mechanisms of xenograft rejection and/or the induction of immune tolerance; (2) develop effective strategies to improve xenograft survival; and (3) characterize and address the physiological compatibility/limitations of xenografts. The long-term goal of this program is to develop strategies for application of xenotransplantation in the clinic.
Funding Opportunity RFA-AI-19-043 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions to participate in the Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP), for the development of preclinical porcine-to-nonhuman primate (NHP) models of pancreatic islet, kidney, heart, lung, or liver xenotransplantation. The goals of this program are to: (1) delineate the cellular and molecular mechanisms of xenograft rejection and/or the induction of immune tolerance; (2) develop effective strategies to improve xenograft survival; and (3) characterize and address the physiological compatibility/limitations of xenografts. The long-term goal of this program is to develop strategies for application of xenotransplantation in the clinic.
Funding Opportunity RFA-AG-20-023 from the NIH Guide for Grants and Contracts. This funding opportunity announcement invites applications to plan and initiate collaborative activities that will develop and implement infrastructure appropriate for an Alzheimer's Disease Research Center (P30).
Funding Opportunity RFA-DA-20-019 from the NIH Guide for Grants and Contracts. This funding opportunity aims to support the development and the application of novel pharmacological approaches to manipulate signaling mediated by endogenous opioid receptors in defined circuits, cell-types or subcellular compartments in live organisms.
Funding Opportunity RFA-AG-20-040 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD.
Notice NOT-HG-19-021 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-19-008 from the NIH Guide for Grants and Contracts. The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Notice NOT-DA-19-042 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-058 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-19-037 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program. Other anticipated benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, thereby allowing investigators to spend more time conducting and overseeing research; and More time for PDs/PIsto mentor junior scientists. Eligibility to apply through this FOA is limited to investigators who currently have at least one active NINDS R01 or R01 equivalent grant (defined here as R00, R01, R37, R56, DP1 or DP2 awards), and who have had an active R01 equivalent grant from NINDS in each of the past 5 years, with no more than one of those years in a no cost extension.
Funding Opportunity PAR-19-289 from the NIH Guide for Grants and Contracts. The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.
Notice NOT-GM-19-044 from the NIH Guide for Grants and Contracts
Notice NOT-GM-19-042 from the NIH Guide for Grants and Contracts